MBX 4291 for Obesity
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new treatment called MBX 4291 to determine its safety and tolerability for people with obesity. Researchers will compare MBX 4291 to a placebo (a harmless pill with no effect) across different groups to identify any side effects. The trial targets adults with obesity (BMI between 30 and 40) whose weight has remained stable for the past three months. Participants should not have conditions like diabetes or specific thyroid issues. As a Phase 1 trial, this research aims to understand how the treatment works in people, offering participants the opportunity to be among the first to receive this new treatment.
Do I have to stop taking my current medications for the trial?
The trial information does not specify if you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
Is there any evidence suggesting that MBX 4291 is likely to be safe for humans?
Research has shown that MBX 4291 appears promising in early lab studies. These studies suggest the treatment might aid in weight loss and could be safe for monthly use. However, this trial is in its initial stages, meaning limited information exists about the safety of MBX 4291 for humans. Early trials like this primarily focus on assessing a treatment's safety, so more details will emerge as the study progresses.12345
Why do researchers think this study treatment might be promising?
Most treatments for obesity focus on lifestyle changes, medications that decrease appetite, or surgery. But MBX 4291 works differently, targeting the underlying biological processes that contribute to obesity. Unlike traditional approaches, MBX 4291 is designed to adjust metabolic pathways, potentially offering a more direct method of weight management. Researchers are excited about this because it could offer a new way to treat obesity that doesn't rely solely on altering diet or exercise patterns. This innovative approach might also lead to more sustainable weight loss results.
What evidence suggests that MBX 4291 might be an effective treatment for obesity?
Research suggests that MBX 4291, which participants in this trial may receive, might aid weight loss in people with obesity. Early studies show it works similarly to some approved drugs that affect hormones controlling hunger and insulin. MBX 4291 is designed for monthly administration, potentially offering more convenience than more frequent treatments. Initial results indicate it could assist with weight loss and is generally well-tolerated. However, these findings are from early studies, and further research is necessary to confirm its effectiveness in people.12356
Are You a Good Fit for This Trial?
This trial is for adults with obesity, which may include those who have struggled with weight since childhood. Participants must meet certain health criteria to join.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment - Single Ascending Dose (SAD)
Participants receive single ascending doses of MBX 4291 or placebo
Treatment - Multiple Ascending Dose (MAD)
Participants receive multiple ascending doses of MBX 4291 or placebo
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- MBX 4291
Trial Overview
The study tests MBX 4291, a new potential treatment for obesity. It involves comparing the effects of this drug against a placebo when given as subcutaneous injections.
How Is the Trial Designed?
3
Treatment groups
Experimental Treatment
Placebo Group
Participants will be administered multiple ascending doses of MBX 4291, or matching placebo.
Participants will be administered single ascending doses of MBX 4291, or matching placebo.
Participants will be administered single or multiple ascending doses of placebo.
Find a Clinic Near You
Who Is Running the Clinical Trial?
MBX Biosciences
Lead Sponsor
Citations
NCT07142707 | A Study to Evaluate the Safety, Tolerability ...
The purpose of this study is to evaluate the safety and tolerability of single and multiple subcutaneous (SC) doses of MBX 4291 in adults with ...
2.
investors.mbxbio.com
investors.mbxbio.com/news-releases/news-release-details/mbx-biosciences-doses-first-participant-phase-1-trial-mbx-4291MBX Biosciences Doses First Participant in Phase 1 Trial of ...
Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291.
3.
clinicaltrialvanguard.com
clinicaltrialvanguard.com/news/mbx-biosciences-announces-ind-submission-of-mbx-4291-for-obesity-treatment/MBX Biosciences Announces IND Submission of ...
Preclinical data suggest MBX 4291 exhibits a similar activity profile and weight loss effect as the currently approved weekly GLP-1/GIP co- ...
MBX Biosciences Reports Third Quarter 2025 Financial ...
MBX 4291. Q4 2026: Results from 12-week multiple ascending dose portion of Phase 1 trial of MBX 4291 for the treatment of obesity. Imapextide.
MBX-4291 - Drug Targets, Indications, Patents
Another drug, nicknamed MBX 4291, entered Phase 1 for obesity earlier this month. The biotech hopes MBX 4291 could compete in the obesity drug market as a once- ...
MBX Biosciences Doses First Participant in Phase 1 Trial of ...
Preclinical data support the potential for improved weight loss and tolerability with once-monthly administration of MBX 4291.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.